Feb 10, 2026 08:45AM
Jan 20, 2026 08:04AM
Jan 20, 2026 08:00AM
Jan 12, 2026 09:01AM
Jan 12, 2026 09:00AM
Dec 3, 2025 08:35AM
Dec 3, 2025 08:35AM Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision Oncology Program into M
Nov 13, 2025 08:30AM
Nov 6, 2025 08:00AM
Oct 30, 2025 08:00AM
Oct 28, 2025 08:50AM
Oct 28, 2025 08:49AM
Oct 24, 2025 08:00AM
Sep 16, 2025 08:29AM Lantern Pharma completes LP-184 phase 1a trial meeting primary endpoints
Sep 16, 2025 08:29AM
Sep 3, 2025 09:44AM
Sep 3, 2025 09:44AM
Aug 19, 2025 08:00AM
Aug 13, 2025 04:30PM
Aug 6, 2025 08:30AM
Aug 6, 2025 08:30AM Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial
Aug 4, 2025 08:55AM
Aug 4, 2025 08:55AM
Jul 31, 2025 07:30AM
Jul 31, 2025 07:30AM
Jul 23, 2025 07:56AM
Jul 23, 2025 07:56AM
Jul 21, 2025 08:20AM Lantern Pharma receives EU patent allowance for AI-developed cancer drug LP-284
Jul 21, 2025 08:20AM
Jul 15, 2025 09:40AM
Jul 15, 2025 09:40AM
Jun 16, 2025 08:30AM
May 29, 2025 08:35AM
May 29, 2025 08:30AM
May 15, 2025 08:45AM Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
May 12, 2025 09:00AM
May 12, 2025 09:00AM
May 8, 2025 08:30AM
May 5, 2025 08:55AM
Mar 27, 2025 04:01PM
Mar 20, 2025 08:00AM
Feb 19, 2025 08:02AM Lantern Pharma (LTRN) Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
Feb 19, 2025 08:00AM
Jan 27, 2025 07:55AM
Dec 9, 2024 08:15AM
Dec 3, 2024 08:05AM
Dec 3, 2024 08:00AM
Nov 26, 2024 08:45AM
Nov 26, 2024 08:45AM Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic L
Nov 19, 2024 08:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All